Article
Author(s):
GeoVax Labs, Inc. (Atlanta, GA, www.geovax.com), has announced an early start of two new acquired immunodeficiency syndrome (AIDS) vaccine clinical (human) trials.
GeoVax Labs, Inc. (Atlanta, GA, www.geovax.com), has announced an early start of two new acquired immunodeficiency syndrome (AIDS) vaccine clinical (human) trials. These FDA-compliant trials were earlier scheduled to start later in 2007 and are the third and fourth in a series of four clinical trials intended to evaluate both human safety and immune responses to GeoVax’s HIV/AIDS vaccines.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.